



Pharmacy Quality Assurance Commission
PO Box 47852 Olympia, WA 98504
www.doh.wa.gov · TDD Relay: 711

To request this document in another format, call 1-800-525-0127. Deaf or hard of hearing customers, please call 711 (Washington Relay) or email doh.information@doh.wa.gov.

January 23, 2026 Weekly Legislative Review Agenda

Time: 12:00 p.m. – 1:00 p.m.
Location: Zoom ID: **863 0929 9195**
<https://us02web.zoom.us/j/86309299195>
Or One tap mobile :
+12532050468,,86309299195# US
+12532158782,,86309299195# US (Tacoma)
In Person: Department of Health
[111 Israel Rd SE](#), #314 (TC2)
Tumwater WA 98501
Contact: Joshua Munroe, Rules and Legislative Consultant, 360.502.5058
Joshua.Munroe@doh.wa.gov
Commission Office: wspqac@doh.wa.gov

No registration needed. **All attendees will join the call with their audio connection muted.**

12:00 p.m.

1. Call to Order
 - 1.1. Roll Call
2. PQAC Bill Report
3. Public Comment Period

1:00 PM (approximately)
Meeting Adjourned

[Link to Washington State Legislature Bill Information 2026](#)

Monday, January 12 – First day of session
 Wednesday, February 4 – Policy committee cutoff **Next cutoff**
 Monday, February 9 – Fiscal committee cutoff
 Tuesday, February 17 – House of origin cutoff

Wednesday, February 25 – Policy committee cutoff (opposite house)
 Monday, March 2 – Fiscal committee cutoff (opposite house)
 Friday, March 6 – Opposite house cutoff
 Thursday, March 12 – Sine die: Last day allowed for regular session under state constitution

TVW - <http://www.tvw.org/>

Focus Bills			
Bill # /Companion	Short Title	Brief Description	Committee Action (subject to change)
HB 2613	Safety and regulatory requirements for compounded medications	<p>Per this bill, drug compounders would not be able to sell, transfer, or distribute drugs compounded under section 503A of the federal Food, Drug, and Cosmetic Act unless a series of conditions are met. These conditions include, but are not limited to, using bulk drug substances that meeting the standards of the U.S. Pharmacopoeia, ensuring those drug substances are a pharmaceutical grade product, conducting and documenting quality control testing of bulk drug substances, and obtaining proof that the bulk drug substances are manufactured under conditions of satisfactory regulatory compliance and oversight.</p> <p>The commission or a duly authorized third party approved by the commission would be allowed to inspect any person or entity that engages in compounding as well as any domestic suppliers, wholesaler, repackagers, or other providers of bulk drug substances for compounding. The commission can take enforcement action for a violation of this bill and write rules to implement the bill.</p> <p>The bill also includes a provision that invalidates any section determined to be in conflict with federal requirements that are a prescribed condition to the allocation of federal funds to the state.</p>	<p>HB 2613 <i>Sponsor(s):</i> Representative Thai <i>Introduction (House):</i> 1/21/2026, referred to Committee on Health Care & Wellness.</p>
SB 5924	Expanding prescriptive	Pharmacists that wish to exercise certain diagnosis and prescriptive authority must enter into a collaborative drug therapy agreement (CDTA) with a licensed physician under current statute. This bill expands the	<p>SB 5924 <i>Sponsor(s):</i> Senators Slatter, Short, Chapman, Conway, Hasegawa,</p>

Focus Bills			
Bill # /Companion	Short Title	Brief Description	Committee Action (subject to change)
	authority for pharmacists	<p>prescriptive authority for pharmacists licensed and practicing in Washington by amending the “practice of pharmacy.” The definition for “practice of pharmacy” in RCW 18.64.011(32) is amended to include “diagnosing and the prescribing or ordering of drugs and devices based on his or her education, training, and experience” as permitted under a pharmacist’s scope of practice.</p> <p>RCW 69.41.030 is also amended to remove a qualifying statement for pharmacists that references a CDTA being a necessary condition for a pharmacist to issue an order or prescription for a legend drug.</p>	<p>Nobles, Orwall, Riccelli, Saldaña, and Shewmake</p> <p><i>Pre-file (Senate): 12/22/2025</i> <i>Introduction (Senate): 1/12/2026,</i> referred to Committee on Health & Long-Term Care.</p>
HB 2302	Expanding prescriptive authority for pharmacists	Companion bill to SB 5924.	<p>HB 2302</p> <p><i>Sponsor(s):</i> Representatives Thai, Macri, Reed, Zahn, Thomas, Stonier, Ormsby, and Hill</p> <p><i>Pre-file (House): 1/7/2026</i> <i>Introduction (House): 1/12/2026,</i> referred to Committee on Health Care & Wellness.</p>
HB 2176	Exempting info in CDTAs from disclosure under the Public Records Act	<p>This bill amends RCW 42.56.360 to exempt collaborative drug therapy agreements (CDTAs) from disclosure under the public records act. Information contained in CDTAs, as well as any attachments or appendices to those CDTAs, are considered confidential and may not be disclosed except under the circumstances outlined in subsection 6(b).</p> <p>Per subsection 6(b), a CDTA or its associated contents may be disclosed if the CDTA is the basis of an order or stipulation finding misconduct resulting in disciplinary action, though personally identifiable information of individuals not facing discipline is still confidential and may not be disclosed. “Personally identifiable information” is defined to include names, mailing addresses, credential numbers, email addresses, practice site facility addresses, and practice site facility phone numbers.</p>	<p>HB 2176</p> <p><i>Sponsor(s):</i> Representatives Thai, Parshley, Ryu, Reed, Zahn, Gregerson, Reeves, and Fosse</p> <p><i>Pre-file (House): 12/19/2025</i> <i>Introduction (House): 1/12/2026,</i> referred to Committee on State Government & Tribal Relations. <i>Public Hearing (State Government & Tribal Relations): 1/14/2026</i></p>

Focus Bills			
Bill # /Companion	Short Title	Brief Description	Committee Action (subject to change)
HB 2198	Integrating executive order 25-03 to improve regulatory efficiency	<p>This bill establishes new reporting and tracking requirements from state agencies to the governor’s office relating to credentialing information. The stated purpose is to provide better information to applicants. The list of agencies defined under RCW 43.42A.010 is expanded, and those agencies must track and record information relating to credential applications such the time it takes to make credential decisions, number of pending and completed applications, and application and credential fee amounts.</p> <p>Each agency must prepare, maintain, and report credentialing information in the statewide credential catalog and central online repository of credential information. RCW 43.42A.030 is amended to list the required elements for each catalog entry, how entries must be updated, and how the state must ensure website and repository accessibility to applicants. Agency performance relating to tracking credential timelines will be posted on the department’s website starting with the 2027 reporting period, and the bill outlines agency deadlines for compiling and reporting credentialing information. If the agency does not meet its published decision deadline after receiving a completed application, it shall refund the application fee.</p>	<p>HB 2198 <i>Sponsor(s):</i> Representatives Richards, Leavitt, Ryu, Dufault, Zahn, Rule, Bronoske, Reeves, and Fosse</p> <p><i>Pre-file (House):</i> 12/26/2025 <i>Introduction (House):</i> 1/12/2026, referred to Committee on State Government & Tribal Relations. <i>Public Hearing (State Government & Tribal Relations):</i> 1/23/2026</p>
SB 5968	Integrating executive order 25-03 to improve regulatory efficiency	Companion bill to HB 2198.	<p>SB 5968 <i>Sponsor(s):</i> Senators Krishnadasan, Liias, and Shewmake</p> <p><i>Introduction (Senate):</i> 1/12/2026, referred to Committee on State Government, Tribal Affairs & Elections. <i>Public Hearing (State Government, Tribal Affairs & Elections):</i> 1/16/2026 <i>Executive Session (State Government, Tribal Affairs & Elections):</i> 1/23/2026</p>

Focus Bills			
Bill # /Companion	Short Title	Brief Description	Committee Action (subject to change)
SB 5921	Psilocybin program	<p>The bill establishes a medical psilocybin program within DOH, and directs DOH to issue licenses to clinicians and producers. Permitted clinicians may write psilocybin authorizations to patients with a “qualifying condition” and explicitly states that determining a qualifying condition is at the sole discretion of the clinician, and all professional liability is borne by the clinician. The bill protects producers, clinicals, and qualified patients from prosecution or penalty for participating in the program but does not protect these entities from liability/prosecution for activities not authorized in the psilocybin act, driving under the influence of psilocybin, or malpractice related to psilocybin treatment. The program excludes synthetic psilocybin.</p> <p>DOH is directed to establish training parameters, treatment and safety protocols, best practices for producers and clinicians, data collection requirements, a registry for psilocybin patients accessible to prescribers, and other requirements to ensure an effective program. The bill also requires the monitoring of producers and clinicians for compliance and rulemaking to outline those compliance requirements, product formulation and preparation standards, and how de-identified patient data may be collected.</p>	<p>SB 5921 <i>Sponsor(s):</i> Senators Salomon, Lovelett, Nobles, Riccelli, Saldaña, Shewmake, and Slatter</p> <p><i>Pre-file (Senate):</i> 12/19/2025 <i>Introduction (Senate):</i> 1/12/2026, referred to Committee on Health & Long-Term Care.</p>

Agency Request Bills			
Bill # /Companion	Short Title	Brief Description	Committee Action (subject to change)
SB 5988	Establishing fee authority for accreditation services provided to opioid treatment programs	SB 5988 allows DOH to apply to the federal Department of Health and Human Services for approval to accredit opioid treatment programs (OTPs). If approved, the department will execute its responsibilities as an accrediting body according to HHS policies and procedures and establish OTP accreditation fees in rule.	<p>SB 5988 <i>Sponsor(s):</i> Senator Robinson; by request of Department of Health</p> <p><i>Pre-file (Senate):</i> 1/5/2026</p>

Agency Request Bills			
Bill # /Companion	Short Title	Brief Description	Committee Action (subject to change)
			<p><i>Introduction (Senate): 1/12/2026, referred to Committee on Ways & Means.</i></p> <p><i>Public Hearing (Ways & Means): 1/19/2026</i></p>
HB 2437	Establishing fee authority for accreditation services provided to opioid treatment programs	Companion bill to SB 5988.	<p>HB 2437</p> <p><i>Sponsor(s): Representatives Lekanoff, Parshley, Ryu, Peterson, Simmons, Ramel, Davis, Macri, and Nance; by request of Department of Health</i></p> <p><i>Introduction (House): 1/13/2026, referred to Committee on Health Care & Wellness.</i></p> <p><i>Public Hearing (Health Care & Wellness): 1/20/2026</i></p>

Additional Bills to Watch			
Bill # /Companion	Short Title	Committee Action (subject to change)	
HB 2145	Protecting patient access to discounted medications and health care services	<p>HB 2145</p> <p><i>Sponsor(s): Representatives Thai, Macri, Obras, Parshley, Tharinger, Salahuddin, Stonier, Berry, Zahn, Bergquist, Lekanoff, Fosse, Stearns, Entenman, Duerr, Wylie, Reed, Fey, Hill, Pollet, Santos, Taylor, Hall,</i></p>	

Additional Bills to Watch		
Bill # /Companion	Short Title	Committee Action (subject to change)
	– 340B drug pricing program	Bernbaum, Berg, Ormsby, Reeves, Ryu, Kloba, Ramel, Doglio, Mena, Cortes, Street, Scott, Thomas, Morgan, Gregerson, Goodman, Farivar, and Davis <i>Introduction (House): 1/12/2026, referred to Committee on Health Care & Wellness. Public Hearing (Health Care & Wellness): 1/20/2026 Executive Session (Health Care & Wellness): 1/23/2026</i>
SB 5981	Protecting patient access to discounted medications and health care services – 340B drug pricing program	<u>SB 5981</u> <i>Sponsor(s):</i> Senators Cleveland, Slatter, Harris, Bateman, Alvarado, Chapman, Dhingra, Frame, Hasegawa, Lias, Nobles, Pedersen, Saldaña, and Valdez <i>Pre-file (Senate): 1/5/2026 Introduction (Senate): 1/12/2026, referred to Committee on Health & Long-Term Care. Public Hearing (Health & Long-Term Care): 1/16/2026</i>
HB 2152	Medical use of cannabis by qualifying patients in specified health care facilities	<u>HB 2152</u> <i>Sponsor(s):</i> Representatives Kloba, Rude, Parshley, Ryu, Chase, Callan, Jacobsen, Fosse, Doglio, Simmons, Scott, Pederson, Reed, Obras, Fitzgibbon, Cortes, Zahn, Wylie, Morgan, Gregerson, Reeves, Farivar, Hill, and Donaghy <i>Introduction (House): 1/12/2026, referred to Committee on Health Care & Wellness. Public Hearing (Health Care & Wellness): 1/13/2026 Executive Session (Health Care & Wellness): 1/21/2026</i>
SB 5900	Medical use of cannabis by qualifying patients in specified health care facilities	<u>SB 5900</u> <i>Sponsor(s):</i> Senators Riccelli, Robinson, Hasegawa, Nobles, Saldaña, and C. Wilson <i>Pre-file (Senate): 12/16/2025 Introduction (Senate): 1/12/2026, referred to Committee on Health & Long-Term Care.</i>
HB 2157	Regulating high-risk AI system development	<u>HB 2157</u> <i>Sponsor(s):</i> Representatives Ryu, Stearns, Ramel, Parshley, Reeves, Reed, Santos, Zahn, Street, Duerr, Gregerson, Ormsby, Scott, Shavers, Thai, Macri, Fosse, Pollet, and Donaghy

Additional Bills to Watch		
Bill # /Companion	Short Title	Committee Action (subject to change)
		<i>Introduction (House): 1/12/2026, referred to Committee on Technology, Economic Development & Veterans</i> <i>Public Hearing (Technology, Economic Development & Veterans): 1/14/2026</i> <i>Executive Session (Technology, Economic Development & Veterans): 1/23/2026</i>
SB 5951	Expanding access to albuterol in public and private schools	SB 5951 <i>Sponsor(s):</i> Senators Cortes, Nobles, Orwall, Slatter, Stanford, and C. Wilson <i>Pre-file (Senate): 12/29/2025</i> <i>Introduction (Senate): 1/12/2026, referred to Committee on Early Learning & K-12 Education</i> <i>Public Hearing (Early Learning & K-12 Education): 1/21/2026</i>
HB 2360	Expanding access to albuterol in public and private schools	HB 2360 <i>Sponsor(s):</i> Representatives Donaghy, Reed, Engell, Bronoske, Zahn, Thomas, Ormsby, Fosse, Salahuddin, Hill, and Pollet <i>Pre-file (House): 1/9/2026</i> <i>Introduction (House): 1/12/2026, referred to Committee on Education</i> <i>Public Hearing (Education): 1/19/2026</i>
HB 2242	Preserving access to preventative services by clarifying state authority and definitions	HB 2242 <i>Sponsor(s):</i> Representatives Bronoske, Doglio, Parshley, Simmons, Berry, Ramel, Thomas, Ormsby, Thai, Macri, Fosse, Pollet, Obras, Wylie, and Zahn; by request of Governor Ferguson and the Insurance Commissioner <i>Introduction (House): 1/12/2026, referred to Committee on Health Care & Wellness</i> <i>Public Hearing (Health Care & Wellness): 1/16/2026</i> <i>Executive Session (Health Care & Wellness): 1/23/2026</i>
SB 5967	Preserving access to preventative services by clarifying state authority and definitions	SB 5967 <i>Sponsor(s):</i> Senators Cleveland, Harris, Hasegawa, Lias, and Pedersen; by request of Governor Ferguson and the Insurance Commissioner <i>Introduction (Senate): 1/12/2026, referred to Committee on Health & Long-Term Care</i> <i>Public Hearing (Health & Long-Term Care): 1/15/2026</i>

Additional Bills to Watch		
Bill # /Companion	Short Title	Committee Action (subject to change)
		<i>Executive Session (Health & Long-Term Care): 1/20/2026</i>
HB 2247	Veterinarian-client-patient relationships	<p><u>HB 2247</u> <i>Sponsor(s):</i> Representatives Parshley, Lekanoff, Reed, Leavitt, Zahn, Gregerson, Berg, and Fosse</p> <p><i>Introduction (House):</i> 1/12/2026, referred to Committee on Health Care & Wellness <i>Public Hearing (Health Care & Wellness):</i> 1/14/2026 <i>Executive Session (Health Care & Wellness):</i> 1/23/2026</p>
SB 6072	Veterinarian-client-patient relationships	<p><u>SB 6072</u> <i>Sponsor(s):</i> Senators Cleveland, Warnick, and Nobles</p> <p><i>Introduction (Senate):</i> 1/13/2026, referred to Committee on Health & Long-Term Care <i>Public Hearing (Health & Long-Term Care):</i> 1/23/2026</p>
HB 2261	Ensuring transparency in credentials and communications between patients and health care professionals	<p><u>HB 2261</u> <i>Sponsor(s):</i> Representatives Marshall and Barnard</p> <p><i>Pre-file (House):</i> 1/6/2026 <i>Introduction (House):</i> 1/12/2026, referred to Committee on Health Care & Wellness <i>Public Hearing (Health Care & Wellness):</i> 1/21/2026</p>
SB 6166	Ensuring transparency in credentials and communications between patients and health care professionals	<p><u>SB 6166</u> <i>Sponsor(s):</i> Senators Muzzall and Chapman</p> <p><i>Introduction (Senate):</i> 1/15/2026, referred to Committee on Health & Long-Term Care</p>
HB 2291	Kratom consumer protection act	<u>HB 2291</u>

Additional Bills to Watch		
Bill # /Companion	Short Title	Committee Action (subject to change)
		<p><i>Sponsor(s):</i> Representatives Reeves, Stonier, Parshley, Leavitt, Gregerson, Goodman, Fosse, Pollet, and Bernbaum</p> <p><i>Pre-file (House):</i> 1/7/2026</p> <p><i>Introduction (House):</i> 1/12/2026, referred to Committee on Consumer Protection & Business</p>
HB 2383	Involuntary treatment act	<p>HB 2383</p> <p><i>Sponsor(s):</i> Representatives Walsh and Graham</p> <p><i>Pre-file (House):</i> 1/9/2026</p> <p><i>Introduction (House):</i> 1/12/2026, referred to Committee on Civil Rights & Judiciary</p>
HB 2453	Psychiatric pharmacists in 23-hour crisis relief centers	<p>HB 2453</p> <p><i>Sponsor(s):</i> Representatives Farivar, Thai, Scott, and Reed</p> <p><i>Introduction (House):</i> 1/13/2026, referred to Committee on Civil Rights & Judiciary</p>
SB 5452	Licensing board-certified psychiatric pharmacists as agency-affiliated counselors	<p>SB 5452</p> <p><i>Sponsor(s):</i> Senators Slatter and Nobles</p> <p><i>Re-Introduction (Senate):</i> 1/12/2026, retained in present status (Committee on Health & Long-Term Care)</p>
HB 1124	Establishing a prescribing psychologist certification	<p>HB 1124</p> <p><i>Sponsor(s):</i> Representatives Simmons, Macri, Senn, Stonier, Ormsby, Tharinger, Kloba, Duerr, Ryu, Morgan, Reed, Callan, Obras, Doglio, Ortiz-Self, Goodman, Reeves, and Hill</p> <p><i>Re-Introduction (House):</i> 1/12/2026, retained in present status (Committee on Health Care & Wellness)</p>
SSB 5112	Establishing a prescribing psychologist certification	<p>SSB 5112</p> <p><i>Sponsor(s):</i> Senators Bateman, Harris, Shewmake, Trudeau, Conway, Nobles, Riccelli, C. Wilson, Robinson, and Hasegawa</p>

Additional Bills to Watch		
Bill # /Companion	Short Title	Committee Action (subject to change)
		<i>Re-Introduction (Senate):</i> 1/12/2026, retained in present status (Rules Committee)
HB 1888	Naturopathic physician scope-of-practice	HB 1888 <i>Sponsor(s):</i> Representatives Berg, Walen, Wylie, Doglio, Ryu, Parshley, Goodman, Santos, Morgan, Duerr, Ramel, Hill, and Macri <i>Re-Introduction (House):</i> 1/12/2026, retained in present status (Committee on Health Care & Wellness)
SB 5765	Psychiatric pharmacists	SB 5765 <i>Sponsor(s):</i> Senators Slatter, Nobles, and Trudeau <i>Re-Introduction (Senate):</i> 1/12/2026, retained in present status (Committee on Health Care & Wellness)
HB 1675	Corporate practice of medicine	HB 1675 <i>Sponsor(s):</i> Representatives Thai and Macri <i>Re-Introduction (House):</i> 1/12/2026, retained in present status (Committee on Health Care & Wellness)
2SSB 5387	Corporate practice of medicine	SB 5387 <i>Sponsor(s):</i> Senators Robinson, Hasegawa, Lias, Nobles, Riccelli, Stanford, and Valdez <i>Re-Introduction (Senate):</i> 1/12/2026, Rules Committee relieved of further consideration. On motion, referred to Ways & Means.
SB 6254	Leveraging AI to streamline regulatory language	SB 6254 <i>Sponsor(s):</i> Senator Braun <i>Introduction (Senate):</i> 1/21/2026, referred to Committee on State Government, Tribal Affairs & Elections

Dead/dormant Bills (relevant if needed to pass the budget)		
Bill # /Companion	Short Title	Bill Summary